📈 Do SIJ lesions progress in #axSpA?

      DESIR cohort (n=649, 10yrs):
      Yes, slowly, but bDMARDs reduce erosion progressi

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      📈 Do SIJ lesions progress in #axSpA? DESIR cohort (n=649, 10yrs): Yes, slowly, but bDMARDs reduce erosion progression #OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
      🔍Can early TNFi beat step-up csDMARDs in pSpA?

      SPARTACUS RCT (n=97) says YES
      60% vs 33% remission at 24 wks

      #EULAR2

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      🔍Can early TNFi beat step-up csDMARDs in pSpA? SPARTACUS RCT (n=97) says YES 60% vs 33% remission at 24 wks #EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
      Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
      safety data
      JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
      2 months ago
      Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
      Can we intercept PsA?

      Retro study 394 PSO pts 17 yrs follow-up 86 PsA

      TNFi linked to higher PsA incidence vs IL- MoA
      T

      Aurelie Najm AurelieRheumo

      2 months ago
      Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14%

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds o

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
      Small interventional synovial biopsy precision medicine study

      CD117 high pts n=15 = better response to IL17i or IL23i i

      Aurelie Najm AurelieRheumo

      2 months ago
      Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment init

      Mrinalini Dey DrMiniDey

      2 months ago
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
      💉 Add tirzepatide to biologics in obese #PsA?

      #POS0050: Yes! Propensity score-matched study (n=93):
      better PROs, HA

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc

      Catch up on Conference Podcasts

      ×